Thomas F Stoop, Rutger T Theijse, Leonard W F Seelen, Bas Groot Koerkamp, Casper H J van Eijck, Christopher L Wolfgang, Geertjan van Tienhoven, Hjalmar C van Santvoort, I Quintus Molenaar, Johanna W Wilmink, Marco Del Chiaro, Matthew H G Katz, Thilo Hackert, Marc G Besselink
Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases with extensive vascular involvement, which can be classified as either borderline resectable pancreatic cancer or locally advanced pancreatic cancer. In these patients, FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy is currently used as preoperative chemotherapy and is eventually combined with radiotherapy. Thus, more patients might reach 5-year overall survival...
November 30, 2023: Nature Reviews. Gastroenterology & Hepatology